Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;77(21):e62-e66.
doi: 10.1158/0008-5472.CAN-17-0582.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Terrence F Meehan  1 , Nathalie Conte  2 , Theodore Goldstein  3 , Giorgio Inghirami  4 , Mark A Murakami  5 , Sebastian Brabetz  6   7 , Zhiping Gu  8 , Jeffrey A Wiser  8 , Patrick Dunn  8 , Dale A Begley  9 , Debra M Krupke  9 , Andrea Bertotti  10 , Alejandra Bruna  11 , Matthew H Brush  12 , Annette T Byrne  13 , Carlos Caldas  11 , Amanda L Christie  5 , Dominic A Clark  2 , Heidi Dowst  14 , Jonathan R Dry  15 , James H Doroshow  16 , Olivier Duchamp  17 , Yvonne A Evrard  18 , Stephane Ferretti  19 , Kristopher K Frese  20 , Neal C Goodwin  21 , Danielle Greenawalt  22 , Melissa A Haendel  12 , Els Hermans  23 , Peter J Houghton  24 , Jos Jonkers  25 , Kristel Kemper  25 , Tin O Khor  26 , Michael T Lewis  27 , K C Kent Lloyd  28 , Jeremy Mason  2 , Enzo Medico  10 , Steven B Neuhauser  9 , James M Olson  29 , Daniel S Peeper  25 , Oscar M Rueda  11 , Je Kyung Seong  30 , Livio Trusolino  10 , Emilie Vinolo  31 , Robert J Wechsler-Reya  32 , David M Weinstock  5 , Alana Welm  33 , S John Weroha  34 , Frédéric Amant  25   35 , Stefan M Pfister  6   7   36 , Marcel Kool  6   7 , Helen Parkinson  2 , Atul J Butte  3 , Carol J Bult  9
Affiliations

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Terrence F Meehan et al. Cancer Res. .

Abstract

Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62-66. ©2017 AACR.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest- S. Ferretti is a laboratory head at Novartis. M.T. Lewis is a manager and limited partner at StemMed Holdings. E. Vinolo is a consultant/advisory board member for EurOPDX Consortium and XenTech. D.M. Weinstock reports receiving a commercial research grant from Novartis, AstraZeneca, Abbvie, Aileron, Roche, and Novartis, has ownership interest (including patents) in Travera, and has provided expert testimony for Monsanto. S.J. Weroha reports receiving a commercial research grant fromNovartis,Genentech, and Tesaro and has ownership interest (including patents) inMayo Clinic Ventures. A.J. Butte is a cofounder and scientific advisor at Personalis, Inc. and NuMedii, Inc., reports receiving a commercial research grant from Progenity, Inc., and has ownership interest (including patents) in NuMedii, Inc. No potential conflicts of interest were disclosed by the other authors.

References

    1. Uthamanthil R, Tinkey P, De Stanchina E. Patient Derived Tumor Xenograft Models Promise, Potential and Practice. Academic Press; 2017.
    1. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. [cited 2017 Jan 31];Cancer Discov [Internet] 2014 4:998–1013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25185190. - PMC - PubMed
    1. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol [Internet] 2012;9:338–50. Available from: http://dx.doi.org/10.1038/nrclinonc.2012.61. - DOI - PMC - PubMed
    1. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: The best laid plans of mice and men. Clin. Cancer Res. 2012:5160–2. - PMC - PubMed
    1. Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. [cited 2017 Apr 18];Nat Rev Cancer [Internet] 2017 17:254–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28104906. - PubMed

Publication types